BioAge Labs Reports Strong Q3 2024 Achievements
BioAge Labs, Inc. ( (BIOA) ) has released its Q3 earnings. Here is a breakdown of the information BioAge Labs, Inc. presented ...
BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates
Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...
BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024
Detailed price information for Bioage Labs Inc (BIOA-Q) from The Globe and Mail including charting and trades.
Business Insider11d
BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024
RICHMOND, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases ...
Mena FN7d
Bioage Labs Reports Third Quarter 2024 Financial Results And Provides Business Updates
Nov. 07, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge",“the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases ...
Nasdaq7d
BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates
RICHMOND, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic ...